相似文献
1
Cetuximab (erbitux).
AJNR Am J Neuroradiol. 2010 Apr;31(4):626-7. doi: 10.3174/ajnr.A2054. Epub 2010 Feb 18.
2
Cetuximab: from bench to bedside.
Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241.
3
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Strahlenther Onkol. 2011 Jan;187(1):32-8. doi: 10.1007/s00066-010-2149-7. Epub 2010 Dec 23.
4
The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. doi: 10.1517/14712598.5.8.1085.
5
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Ann Oncol. 2011 Feb;22(2):486-7. doi: 10.1093/annonc/mdq744. Epub 2011 Jan 13.
6
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Lancet Oncol. 2012 Mar;13(3):233-4. doi: 10.1016/s1470-2045(12)70044-x.
7
Cetuximab: appraisal of a novel drug against colorectal cancer.
Recent Results Cancer Res. 2007;176:135-43. doi: 10.1007/978-3-540-46091-6_11.
8
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7.
9
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36. doi: 10.1053/sonc.2002.31525.
10
The price tag on progress--chemotherapy for colorectal cancer.
N Engl J Med. 2004 Jul 22;351(4):317-9. doi: 10.1056/NEJMp048143.
引用本文的文献
1
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.
Vaccines (Basel). 2025 Jun 26;13(7):689. doi: 10.3390/vaccines13070689.
2
Fluorescence Imaging-Assessed Surgical Margin Detection in Head and Neck Oncology by Passive and Active Targeting.
Mol Diagn Ther. 2025 May 8. doi: 10.1007/s40291-025-00781-x.
3
Targeted cancer treatment using a novel EGFR-specific Fc-fusion peptide based on GE11 peptide.
Sci Rep. 2025 Feb 11;15(1):5107. doi: 10.1038/s41598-025-89143-5.
4
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.
Pharmaceutics. 2025 Jan 16;17(1):121. doi: 10.3390/pharmaceutics17010121.
5
A Case of Posterior Reversible Encephalopathy Syndrome Associated With Pembrolizumab and Cetuximab Combination Therapy.
Cureus. 2024 Oct 19;16(10):e71867. doi: 10.7759/cureus.71867. eCollection 2024 Oct.
6
Anti-anemic potential of L. in iron-deficient rat model; network pharmacology profiling.
Food Sci Nutr. 2024 Jul 21;12(10):7331-7346. doi: 10.1002/fsn3.4314. eCollection 2024 Oct.
7
Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.
Sci Rep. 2024 May 9;14(1):10642. doi: 10.1038/s41598-024-59676-2.
8
A Multifunctionalized Potyvirus-Derived Nanoparticle That Targets and Internalizes into Cancer Cells.
Int J Mol Sci. 2024 Apr 13;25(8):4327. doi: 10.3390/ijms25084327.
9
Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift.
AAPS PharmSciTech. 2024 Mar 1;25(3):52. doi: 10.1208/s12249-024-02759-0.
10
Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.
Drug Deliv Transl Res. 2024 Nov;14(11):3147-3162. doi: 10.1007/s13346-024-01536-7. Epub 2024 Feb 21.
本文引用的文献
1
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Am J Clin Oncol. 2010 Apr;33(2):144-7. doi: 10.1097/COC.0b013e3181979093.
2
Emerging profile of cetuximab in non-small cell lung cancer.
Lung Cancer. 2010 Jun;68(3):332-7. doi: 10.1016/j.lungcan.2009.07.012. Epub 2009 Sep 26.
3
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):9-15. doi: 10.1016/j.ijrobp.2009.04.060. Epub 2009 Sep 8.
4
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Clin Exp Immunol. 2009 Oct;158(1):1-9. doi: 10.1111/j.1365-2249.2009.03992.x.
5
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.
6
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
7
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.
Value Health. 2008 Sep-Oct;11(5):791-9. doi: 10.1111/j.1524-4733.2007.00302.x. Epub 2008 Jan 11.
8
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
Drugs. 2007;67(17):2585-607. doi: 10.2165/00003495-200767170-00008.
9
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Clin Cancer Res. 2007 Mar 1;13(5):1540-51. doi: 10.1158/1078-0432.CCR-06-1887.
10
Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Clin Ther. 2005 Jun;27(6):684-94. doi: 10.1016/j.clinthera.2005.06.003.
Zotero 插件